RPHM实时信号 | 通过Getagraph.com最大化利润

购买 145840 min ago

@ $1.715

发出时间: 10 Feb 2024 @ 00:54

回报率: 10.79%

上一信号: Feb 9 - 23:42

上一信号: 出售

回报率: 0.42 %

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 04:00):

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases...

Stats
今日成交量	274 714
平均成交量	278 300
市值	63.50M
EPS	$0 ( 2024-05-09 )
下一个收益日期	( $-0.170 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.880
ATR14	$0.00400 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-14	Leonard Braden Michael	Buy	335 000	Common Stock
2024-05-14	Leonard Braden Michael	Buy	79 281	Common Stock
2024-05-14	Leonard Braden Michael	Buy	0	Common Stock
2024-05-14	Leonard Braden Michael	Sell	0	Common Stock
2023-08-28	Hall Ashley	Sell	15 625	Stock option (right to buy)

INSIDER POWER
71.20
Last 94 transactions
Buy: 16 229 361 \| Sell: 47 287 756

音量相关性

長: 0.04 (neutral)

短: 0.74 (moderate)

Signal:(49.088) Neutral

Reneo Pharmaceuticals, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Reneo Pharmaceuticals, 相关性 - 货币/商品

0.87
( strong )

0.91
( very strong )

0.00
( neutral )

0.89
( strong )

0.00
( neutral )

0.23
( neutral )

Reneo Pharmaceuticals, 财务报表

Annual	2023
营收:	$0
毛利润:	$-525 000 (0.00 %)
EPS:	$-2.52

FY	2023
营收:	$0
毛利润:	$-525 000 (0.00 %)
EPS:	$-2.52

FY	2022
营收:	$0
毛利润:	$-529 000 (0.00 %)
EPS:	$-2.04

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-5.11

Financial Reports:

No articles found.

Reneo Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Reneo Pharmaceuticals,

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.